insitro’s Acquisition Of Haystack Sciences

Sidley Austin LLP advised Haystack Sciences on the deal.

insitro, a machine learning driven drug discovery and development company, announced the acquisition of Haystack Sciences, a private company advancing proprietary methods to drive machine-learning enabled drug discovery. Haystack’s approach focuses on synthesizing, breeding and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences called DNA-encoded libraries, or DELs. Financial details of the acquisition are not disclosed.

insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D.

Haystack Sciences seeks to inform and speed drug discovery by acquiring data of best-in-class accuracy and dimensionality from DNA Encoded Libraries (DELs). This is enabled by proprietary technologies for in vitro evolution of fully synthetic small molecules and high throughput mapping of structure-activity relationships for selection of molecules with drug-like properties.

The Sidley team was led by Josh DuClos (Picture), Mehdi Khodadad, Anthony Friedman and Patrick Sims.

Involved fees earner: Joshua DuClos – Sidley Austin LLP; Anthony James Friedman – Sidley Austin LLP; Mehdi Khodadad – Sidley Austin LLP; Patrick Sims – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Haystack Sciences;

Author: Ambrogio Visconti